Platelet BioGenesis Revenue and Competitors
Estimated Revenue & Valuation
- Platelet BioGenesis's estimated annual revenue is currently $542.5k per year.
- Platelet BioGenesis's estimated revenue per employee is $77,500
- Platelet BioGenesis's total funding is $132.1M.
Employee Data
- Platelet BioGenesis has 7 Employees.
- Platelet BioGenesis grew their employee count by -42% last year.
Platelet BioGenesis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Co-founder | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Research Associate | Reveal Email/Phone |
Platelet BioGenesis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Platelet BioGenesis?
Platelet BioGenesis is developing technology to produce the world's first donor-independent human platelets from human induced pluripotent stem cells. This technology will bridge the gap from megakaryocyte to platelet. Platelets are the ‘bandaids' of the bloodstream, responsible for clot formation and blood vessel repair. Over 2 million Americans receive platelet transfusions annually that dramatically increase survival rates for cancer, transplant, and surgery patients.
keywords:N/A
$132.1M
Total Funding
7
Number of Employees
$542.5k
Revenue (est)
-42%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Platelet BioGenesis News
Integra LifeSciences, Platelet BioGenesis, Avita Medical, Stratatech, Organogenesis, Smith & Nephew, Acell, Symatese.
Platelet Biogenesis Inc. has resolved litigation against a venture capital investor that claimed it was duped by the biotech company's...
Venture capital firm Symbiosis II LLC filed suit in Delaware against Platelet Biogenesis Inc., claiming it was duped into investing by the...
Platelet BioGenesis, Inc. (PBG), a Cambridge, Mass.-based leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, raised more than $26m in Series A-1 financing. The round, which brought total funding to approximately $45m, was co-led by Ziff Capital Part ...
CAMBRIDGE, Mass.,--(BUSINESS WIRE)--Platelet BioGenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+) and platelet-based therapeutics, announced today that it has raised more than $26 million in Series A-1 financing. This round – in addition to Series A financin ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 7 | -53% | $7.9M |
#2 | $0.1M | 7 | 0% | $24M |
#3 | $0.1M | 7 | -78% | $21.8M |
#4 | $0.5M | 7 | -36% | N/A |
#5 | $0.9M | 7 | 0% | N/A |